一个β-阻断剂的β3AR激动剂活性的分子机制
Shuang Zheng1,2, Shuhao Zhang1,2, Shengjie Dai3,4
1State Key Laboratory of Membrane Biology, Tsinghua-Peking Center for Life Sciences, School of Pharmaceutical Sciences, Tsinghua University, Beijing, 100084, P. R. China.
ChemPlusChem
|July 24, 2024
概括
开发针对β-上腺素受体 (βARs) 的选择性药物是一项挑战. 这项研究揭示了卡拉佐洛尔如何对β3AR和β2AR有不同的作用,指导制造更有效的β3AR激动剂.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 生物化学 生物化学
背景情况:
- 开发G蛋白结合受体 (GPCRs) 的亚型选择性药物,如β-上腺素受体 (βARs),由于高度的亚型相似性,很难.
- β3AR激动剂在过度活动的膀和早产方面具有治疗潜力,但对β1AR和β2AR产生非目标效应.
- 表现出β3AR激动剂活性的β-抑制剂背后的机制尚不清楚,这阻碍了选择性药物开发.
研究的目的:
- 阐明卡拉佐洛尔在β3AR和β2AR的不同活性背后的分子机制.
- 为设计具有减少目标外影响的选择性β3AR激动剂提供结构洞察力.
主要方法:
- 使用X射线晶体学确定了与上腺素或卡拉佐洛尔复合的人类β3AR的结构.
- 进行了突变遗传学研究,以调查特定氨基酸残留物的作用.
- 利用分子动力学模拟来分析受体灵活性和相互作用.
主要成果:
- 结构分析显示,D3.32残留物灵活性上的差异有助于卡拉佐洛尔的明显对抗剂 (β2AR) 和激动剂 (β3AR) 活性.
- 细胞外循环 (ECL),特别是ECL1,间接地影响了这个过程.
- 卡拉佐洛尔作为β阻塞剂和β3AR激动剂的双重活性是由结构灵活性差异解释的.
结论:
- D3.32的灵活性是carazolol在β2AR和β3AR的差异活性的一个关键决定因素.
- 细胞外循环相互作用在受体药理学中起着调节作用.
- 这些发现为开发用于治疗应用的新型选择性β3AR激动剂提供了关键指导.
更多相关视频
相关概念视频
Adrenergic Antagonists: ɑ and β-Receptor Blockers
429
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
429
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
561
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
561
Antihypertensive Drugs: Types of β-Blockers
623
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
623
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
617
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
617
Antihypertensive Drugs: Action of β1 Blockers
396
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
396
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
842
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
842


